

# Zafgen

## Successful IPO to advance beloranib

In June 2014, Zafgen raised net proceeds of \$103m from a 6.9m share initial public offering (IPO) at \$16 per share. Studies for obesity drug beloranib ranging from Phase IIa to Phase III are planned through 2015. Zafgen plans to conduct a Phase IIb study before starting Phase III in the general population setting. Lacklustre sales of newly marketed obesity drugs from Arena and Vivus support a long-term opportunity, given beloranib's unique mechanism of action, and favourable data to date.

## IPO proceeds to fund broad beloranib programme

Zafgen ended Q214 with \$134m in cash. It plans to conduct a Phase III beloranib study in rare genetic disease Prader-Willi Syndrome, which affects between 1:8,000 and 1:50,000 globally, and has been granted orphan drug designation in the US and Europe. This niche indication could provide a faster path to market, and premium pricing potential. Zafgen plans a Phase IIb in severe obesity in the general population; its Phase IIa hypothalamic injury related obesity study is 50% recruited.

## Beloranib a first-in-class obesity medicine

Beloranib's unique mechanism of action reduces hunger while stimulating the use of stored fat as an energy source by inhibiting production of enzyme MetAP2. In contrast, the current class of marketed obesity drugs target the brain to elicit a non-hunger response. Beloranib has shown comparable efficacy in an early study, but saw no serious adverse events in Phase IIa, while Belviq and Qsymia have been linked to depression and cardiovascular risks, among others. Such results could overcome its subcutaneous administration compared with orally dosed incumbents.

## Weak launch of competitors provides opportunity

In 2012, Belviq (Arena/Eisai) and Qsymia (Vivus) were FDA approved for obesity. A third drug, Orexigen's Contrave, could be approved before the end of 2014. Despite one-third of the US adult population being obese, Belviq and Qsymia have performed below expectations, with Q214 sales of \$11m and \$9.1m, respectively.

## Valuation: Reflects development stage for beloranib

Zafgen has a current EV of \$299m, reflecting its development stage compared with the EVs of Arena (\$729m), Orexigen (\$682m) and Vivus (\$344m); it is most aligned with Vivus, which, unlike the others, has not partnered its drug Qsymia. Beloranib offers a novel mechanism of action. Development and regulatory progress should unlock significant upside, particularly if better efficacy and safety is confirmed.

### Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	0.00	(14.03)	(3.11)	N/A	N/A	N/A
12/14e	0.08	(47.03)	(5.27)	N/A	N/A	N/A
12/15e	0.00	(65.55)	(2.76)	N/A	N/A	N/A


Source: Company reports, Thomson Datastream

### Pharma & biotech

20 August 2014

**Price** **\$19.07**  
**Market cap** **\$433m**

### Share price graph



### Share details

Code ZFGN  
 Listing NASDAQ  
 Shares in issue 22.7m

### Business description

Zafgen Inc. is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Its lead product candidate beloranib is a novel, first-in-class twice-weekly subcutaneous injection for treatment of obesity related conditions.

### Bull

- Solid efficacy and safety profile to date.
- New mechanism of action vs marketed obesity drugs.
- Well funded to advance beloranib to pivotal studies.

### Bear

- Commercialisation of obesity drugs has been challenging.
- Beloranib is years from market.
- Efficacy and safety data yet to be confirmed in larger studies.

### Analysts

Steven Silver +44 (0)20 3077 5700  
 Dr Mick Cooper +44 (0)20 3077 5734  
[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

**EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.**

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(i)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.